Pfizer [PFIZER] vs Concord Biotech [CONCORDBIO] Detailed Stock Comparison

Pfizer Ltd.

NSE
Loading...

Concord Biotech Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Pfizer Ltd. wins in 16 metrics, Concord Biotech Ltd. wins in 4 metrics, with 0 ties. Pfizer Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Pfizer Ltd. Concord Biotech Ltd. Better
P/E Ratio (TTM) 25.56 34.14 Pfizer Ltd.
Price-to-Book Ratio 5.66 5.86 Pfizer Ltd.
Debt-to-Equity Ratio 2.33 0.09 Concord Biotech Ltd.
PEG Ratio 2.28 -2.10 Pfizer Ltd.
EV/EBITDA 22.48 24.23 Pfizer Ltd.
Profit Margin (TTM) 34.39% 26.97% Pfizer Ltd.
Operating Margin (TTM) 33.17% 28.89% Pfizer Ltd.
EBITDA Margin (TTM) 33.17% 28.89% Pfizer Ltd.
Return on Equity 18.20% 20.50% Concord Biotech Ltd.
Return on Assets (TTM) 15.63% 18.27% Concord Biotech Ltd.
Free Cash Flow (TTM) $6.32B $1.33B Pfizer Ltd.
Dividend Yield 1.27% 0.44% Pfizer Ltd.
1-Year Return -23.35% -35.83% Pfizer Ltd.
Price-to-Sales Ratio (TTM) 8.78 9.18 Pfizer Ltd.
Enterprise Value $194.17B $104.46B Pfizer Ltd.
EV/Revenue Ratio 7.82 9.02 Pfizer Ltd.
Gross Profit Margin (TTM) 65.15% 76.33% Concord Biotech Ltd.
Revenue per Share (TTM) $543 $110 Pfizer Ltd.
Earnings per Share (Diluted) $186.40 $29.77 Pfizer Ltd.
Beta (Stock Volatility) 0.17 0.58 Pfizer Ltd.

Pfizer Ltd. vs Concord Biotech Ltd. Stock Performance Analysis

Loading Price Chart...

PFIZER
CONCORDBIO

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Pfizer Ltd.0.20%-0.22%-8.81%-4.87%-9.94%-8.09%
Concord Biotech Ltd.1.95%15.33%21.57%19.18%1.44%3.29%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Pfizer Ltd.-23.35%16.94%-16.55%139.64%232.33%479.18%
Concord Biotech Ltd.-35.83%43.59%43.59%43.59%43.59%43.59%

Performance & Financial Health Analysis: Pfizer Ltd. vs Concord Biotech Ltd.

MetricPFIZERCONCORDBIO
Market Information
Market Cap i₹218.82B₹106.31B
Market Cap CategoryLarge capMid cap
10 Day Avg. Volume i14,470361,672
90 Day Avg. Volume i18,450257,270
Last Close₹4,518.00₹1,380.20
52 Week Range₹4,396.70 - ₹5,993.00₹987.00 - ₹2,146.00
% from 52W High-24.61%-35.68%
All-Time High₹6,451.15 (Sep 02, 2024)₹2,664.00 (Sep 16, 2024)
% from All-Time High-29.97%-48.19%
Growth Metrics
Quarterly Revenue Growth0.20%0.14%
Quarterly Earnings Growth0.11%-0.15%
Financial Health
Profit Margin (TTM) i0.34%0.27%
Operating Margin (TTM) i0.33%0.29%
Return on Equity (TTM) i0.18%0.21%
Debt to Equity (MRQ) i2.330.09
Cash & Liquidity
Book Value per Share (MRQ)₹841.24₹173.32
Cash per Share (MRQ)₹591.12₹31.25
Operating Cash Flow (TTM) i₹9.08B₹2.98B
Levered Free Cash Flow (TTM) i₹7.68B₹3.72B
Dividends
Last 12-Month Dividend Yield i1.27%0.44%
Last 12-Month Dividend i₹70.00₹8.75

Valuation & Enterprise Metrics Analysis: Pfizer Ltd. vs Concord Biotech Ltd.

MetricPFIZER (Apr 24, 2026)CONCORDBIO (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i25.5634.14
Forward P/E i25.1526.89
PEG Ratio i2.28-2.10
Price to Sales (TTM) i8.789.18
Price to Book (MRQ) i5.665.86
Market Capitalization
Market Capitalization i₹218.82B₹106.31B
Enterprise Value i₹194.17B₹104.46B
Enterprise Value Metrics
Enterprise to Revenue i7.829.02
Enterprise to EBITDA i22.4824.23
Risk & Other Metrics
Beta i0.170.58
Book Value per Share (MRQ) i₹841.24₹173.32

Financial Statements Comparison: Pfizer Ltd. vs Concord Biotech Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricPFIZER (2025)CONCORDBIO (2025)
Revenue/Sales i22.81B11.80B
Cost of Goods Sold i8.13B3.18B
COGS % of Revenue i35.6%26.9%
Gross Profit i14.68B8.62B
Gross Margin i64.4%73.1%
Research & Development iN/AN/A
Operating Income (EBIT) i6.81B4.63B
Operating Margin i29.9%39.3%
EBITDA i9.13B5.27B
EBITDA Margin i40.0%44.7%
Pre-Tax Income i10.16B4.95B
Pre-Tax Income % of Revenue i44.5%41.9%
Income Tax i2.48B1.23B
Income Tax % of Revenue i10.9%10.4%
Net Income (Profit) i7.68B3.72B
Profit Margin i33.7%31.5%

Balance Sheet & Liquidity Metrics

MetricPFIZER (2025)CONCORDBIO (2025)
Cash & Equivalents i4.95B9.05M
Total Current Assets i35.13B11.35B
Total Current Assets % of Revenue i154.0%96.2%
Total Current Liabilities i5.70B1.84B
Total Current Liabilities % of Revenue i25.0%15.6%
Long-Term Debt i676.20M6.30M
Long-Term Debt % of Revenue i3.0%0.1%
Total Shareholders Equity i42.17B18.13B
Retained Earnings i24.36B16.91B
Retained Earnings % of Revenue i106.8%143.3%
Property, Plant & Equipment i1.72B667.94M

Cash Flow Statement Comparison

MetricPFIZER (2025)CONCORDBIO (2025)
Operating Cash Flow i9.08B2.98B
Operating Cash Flow % of Revenue i39.8%25.3%
Capital Expenditures i1.24B-1.11B
Free Cash Flow i6.32B1.33B
FCF Margin i27.7%11.3%
Debt Repayment iN/A-58.59M
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricPFIZERCONCORDBIO
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i45.75M104.62M
Float Shares i15.10M26.95M
% Held by Insiders i66.98%74.26%
% Held by Institutions i16.80%13.16%
% Held by Public i16.22%12.58%

Dividend Analysis & Yield Comparison: Pfizer Ltd. vs Concord Biotech Ltd.

MetricPFIZERCONCORDBIO
Last 12-Month Dividend i₹70.00₹8.75
Last 12-Month Dividend Yield i1.27%0.44%
3-Year Avg Annual Dividend i₹46.67₹2.92
3-Year Avg Dividend Yield i0.58%0.56%
3-Year Total Dividends i₹140.00₹8.75
Ex-Dividend DateJul 09, 2025Jun 21, 2024